Harmony Biosciences is a neuroscience-focused pharmaceutical company that develops treatments for rare neurological diseases across sleep/wake disorders, rare epilepsy, and neurobehavioral conditions. The company's primary revenue source is WAKIX (pitolisant), an FDA-approved, non-controlled oral medication for narcolepsy that treats excessive daytime sleepiness and cataplexy in adults and children; it is the only approved narcolepsy treatment that is not a scheduled controlled substance, and is sold through specialty pharmacy distributors. Beyond its commercial product, Harmony maintains a development pipeline including next-generation pitolisant formulations and indication expansions in sleep disorders, an oral 5HT-2 receptor agonist in Phase 3 trials for rare epilepsies, orexin and melanin-concentrating hormone receptor agonists for sleep and metabolic disorders, and neurobehavioral programs; the company outsources manufacturing to contract manufacturers and has licensed rights to its core intellectual property from Bioprojet with patent coverage extending to 2030 and beyond for newer formulations.